Auxilium sues Watson on testosterone gel patent

Thu May 24, 2012 6:11pm IST

Related Topics

Stocks

   

(Reuters) - Auxilium Pharmaceuticals Inc sued Watson Pharmaceuticals Inc alleging that it infringed patents related to Auxilium's testosterone gel Testim.

A unit of Watson had filed with U.S. health regulators last month for the approval of a generic version of Testim.

As a result of the lawsuit, regulatory approval of Watson's generic version will be stayed for 30 months, or until the litigation is resolved, Auxilium said.

In its suit, Auxilium alleged that Watson's gel infringed ten patents that are expected to expire between 2023 and 2025.

Auxilium had entered into a co-promotion agreement with a unit of GlaxoSmithKline on Monday to jointly sell Testim.

Shares of Auxilium, which have risen 10 percent since the company entered into the GlaxoSmithKline agreement, closed at $19.23 on Wednesday on the Nasdaq. Watson shares were at $70.71 at close on the New York Stock Exchange on Wednesday.

(Reporting by Adithya Venkatesan in Bangalore; Editing by Sreejiraj Eluvangal)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Ebola Outbreak

HEALTH SHOWCASE

H5N6 Bird Flu

H5N6 Bird Flu

China poultry farm hit in new outbreak of H5N6 bird flu.  Full Article 

Weight Loss

Weight Loss

Low-carb diets may beat low-fat options for weight loss, heart health.  Full Article 

TV and Snacking

TV and Snacking

High-action TV shows lead to more snacking: study.  Full Article 

Fighting Cyberbullies

Fighting Cyberbullies

Family dinners may help kids cope with cyberbullying.  Full Article 

Price Factor

Price Factor

Pricing is key for new heart drugs challenging cheap generics.  Full Article 

Diabetes Care

Diabetes Care

Pistachios may help reduce diabetes risk: study.  Full Article 

'Exciting' Drug

'Exciting' Drug

'Most exciting ever' Novartis drug points to huge sales.  Full Article